Comparing the efficacy and safety of faecal microbiota transplantation with bezlotoxumab in reducing the risk of recurrent Clostridium difficile infections: a systematic review and Bayesian network meta-analysis of randomised controlled trials

OBJECTIVES: The risk of recurrent Clostridium difficile infections (RCDIs) is high when treated with standard antibiotics therapy (SAT) alone. It is suggested that the addition of faecal microbiota transplantation (FMT) or bezlotoxumab after SAT reduces the risk of RCDI. In the absence of head-to-he...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhifany, Abdullah A, Almutairi, Abdulaali R, Almangour, Thamer A, Shahbar, Alaa N, Abraham, Ivo, Alessa, Mohammed, Alnezary, Faris S, Cheema, Ejaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858162/
https://www.ncbi.nlm.nih.gov/pubmed/31699731
http://dx.doi.org/10.1136/bmjopen-2019-031145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858162/
https://www.ncbi.nlm.nih.gov/pubmed/31699731
http://dx.doi.org/10.1136/bmjopen-2019-031145

Ejemplares similares